Anonymous
Guest
Anonymous
Guest
Given Roche’s expertise in diagnostics, genomics and drug discovery – there are 68 new molecular entities in its pharma pipeline – shareholders could be handsomely rewarded in coming years as the company expands its leadership position from oncology to related fields, such as immunology and neuroscience. - See more at: http://ycharts.com/analysis/story/r...ipelines_lets_talk_roche#sthash.3f1aD0FQ.dpuf